RecruitingNot ApplicableNCT06689241
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial
Sponsor
Alexandria University
Enrollment
162 participants
Start Date
Oct 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial
Eligibility
Min Age: 20 YearsMax Age: 60 Years
Inclusion Criteria3
- Age: 20-60 years, both sexes.
- ASA physical status class I to III.
- BMI 35-50 kg/m²
Exclusion Criteria4
- Severe cardiac disorder
- chronic renal failure
- liver cirrhosis
- major psychological disorder
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEnoxaparin
40mg
DRUGrivaroxaban
10mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06689241
Related Trials
RemI for Post-Bariatric Surgery Weight Regain
NCT062929362 locations
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
NCT062937031 location
Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial
NCT055314741 location
Comorbidities Resolution After MGB Surgery and Change in Body Composition
NCT060156201 location
Impact GLP-1 Agonists Following Bariatric
NCT061324771 location